Posts by Sandra Ansanay-Alex
Duhn Therapeutics signs global license agreement with OM Pharma
Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a global biopharmaceutical company and leader in bacterial lysate products, announce an exclusive licence agreement to advance the development and commercialization of lead candidate DHN198, previously OM-174, in a pipeline of lipid-based cancer immunotherapies. Duhn Therapeutics, with executive…
Read MoreONWARD Medical raises CHF 50 million
ONWARD Medical N.V.announces that it successfully raised an amount of EUR 50 million led by a cornerstone investment from Ottobock, a German global leader in prosthetics, orthotics, and exoskeleton technology. The investment is extending the company’s cash runway to two years or more, providing ample capital to fuel its transition to a commercial enterprise, and…
Read More100 new jobs and a new plant for Lonza in Visp
Lonza is expanding its partnership with an undisclosed major pharmaceutical company to supply antibody-drug conjugates (ADCs). This agreement includes building a new facility at Lonza’s Ibex® Biopark in Visp, Switzerland, and providing large-scale production of monoclonal antibodies for a new ADC treatment. Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical…
Read MoredEEGtal awarded during the 18th HUG Innovation Day
Geneva University Hospitals (HUG) awarded the 2024 Innovation Prize to three projects: dEEGtal, an artificial intelligence-assisted biomarker for the early diagnosis of epilepsy; 3Dneointub8, a training device for nasotracheal intubation of infants; and Prestapp, a navigation aid for the healthcare network. As a bridge between the worlds of hospitals, universities and business, Innovation…
Read MoreAktiia Gets CE-mark Approval For CALFREE as a Class II medical product
Swiss healthcare technology company Aktiia has achieved a major milestone with the CE-mark approval of its groundbreaking CALFREE technology as a Class II medical product. This new technology allows for calibration-free blood pressure monitoring using optical sensors found in common devices like smartwatches and smartphone cameras, transforming the way blood pressure is tracked and managed.…
Read MoreFinalSpark’s Neuroplatform: the era of organic computing has begun!
Swiss startup FinalSpark has just launched its Neuroplatform, the world’s first commercial bioprocessor. This innovation promises to be a technological and energy revolution, with the potential to disrupt the field of artificial intelligence FinalSpark’s Neuroplatform: A Radical Approach What makes FinalSpark’s research groundbreaking is the fact that FinalSpark lab is fully accessible remotely, as…
Read MoreLymphatica Medtech Closes € 17.9 M Series B Funding Round
Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions…
Read MoreNovostia Secures Additional CHF 5.6 million in Funding and Announces New CEO
Novostia, a Biopôle-based pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s development efforts and advance its clinical evidence base. Appointment of New CEO…
Read MoreSilvia Scherer, from APTISSEN SA, is Entrepreneur of the Year
On 4 October 2024, Silvia Sherer, co-founder of APTISSEN, became Swiss Entrepreneur of the Year in the category Industry, High-Tech & Life Sciences during a ceremony in Lucerne. Aptissen SA is a Geneva-based biomedical company specializing in the development and commercialization of innovative medical devices, primarily focused on treating osteoarticular conditions, such as…
Read MoreAtinary Technologies Announces Strategic Collaboration with Snapdragon Chemistry
Atinary Technologies has joined forces with Snapdragon Chemistry, a Cambrex subsidiary, to bring AI-driven automation into pharmaceutical process development By integrating Atinary’s no-code AI platform, SDLabs™, and Snapdragon’s LabOS™ software, the partnership has developed an automated Solid-Phase Oligonucleotide Synthesizer (SPOS), designed to optimize drug synthesis processes autonomously. This collaboration aims to improve efficiency…
Read More